A cell permeable peptide analog as a potential-specific PET imaging probe for prostate cancer detection

Guiyang Hao, Jian Zhou, Yi Guo, Michael A. Long, Tiffani Anthony, Jennifer Stanfield, Jer Tsong Hsieh, Xiankai Sun

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Non-invasive detection of prostate cancer or metastases still remains a challenge in the field of molecular imaging. In our recent work of screening arginine- or lysine-rich peptides for intracellular delivery of a therapeutic agent into prostate cancer cells, an arginine-rich cell permeable peptide (NH2GR11) was found with an unexpectedly preferential uptake in prostate cancer cell lines. The goal of this work was to develop this peptide as a positron emission tomography (PET) imaging probe for specific detection of distant prostate cancer metastases. The optimal length of arginine-rich peptides was evaluated by the cell uptake efficiency of three fluorescein isothiocyanate (FITC)-tagged oligoarginines (NHGR9, NHGR11, and NHGR13) in four human prostate cell lines (LNCaP, PZHPV- 7, DU145, and PC3). Of the three oligoarginines, NH 2GR11 showed the highest cell uptake and internalization efficiency with its subcellular localization in cytosol. The biodistribution of FITC-NHGR9, FITC-NHGR11, and FITC-NHGR13 performed in control nude mice displayed the unique preferential accumulation of FITC-NHGR11 in the prostate tissue. Further in vivo evaluation of FITCNHGR11 in PC3 tumor-bearing nude mice revealed elevated uptake of this peptide in tumors as compared to other organs. In vivo pharmacokinetics evaluated with 64Cu-labeled NH2GR11 showed that the peptide was rapidly cleared from the blood (t1/2 = 10.7 min) and its elimination half-life was 17.2 h. The PET imaging specificity of 64Cu-labled NH2GR11 was demonstrated for the detection of prostate cancer in a comparative imaging experiment using two different human cancer xenograft models.

Original languageEnglish (US)
Pages (from-to)1093-1101
Number of pages9
JournalAmino Acids
Volume41
Issue number5
DOIs
StatePublished - Nov 2011

Fingerprint

Positron emission tomography
Positron-Emission Tomography
Fluorescein
Prostatic Neoplasms
Imaging techniques
Peptides
Arginine
Cells
Nude Mice
Tumors
Prostate
Bearings (structural)
Neoplasm Metastasis
Molecular imaging
Cell Line
Neoplasms
Molecular Imaging
Pharmacokinetics
Heterografts
Cytosol

Keywords

  • Cu
  • Cell permeable peptide
  • PET
  • Prostate cancer

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Organic Chemistry

Cite this

A cell permeable peptide analog as a potential-specific PET imaging probe for prostate cancer detection. / Hao, Guiyang; Zhou, Jian; Guo, Yi; Long, Michael A.; Anthony, Tiffani; Stanfield, Jennifer; Hsieh, Jer Tsong; Sun, Xiankai.

In: Amino Acids, Vol. 41, No. 5, 11.2011, p. 1093-1101.

Research output: Contribution to journalArticle

Hao, Guiyang ; Zhou, Jian ; Guo, Yi ; Long, Michael A. ; Anthony, Tiffani ; Stanfield, Jennifer ; Hsieh, Jer Tsong ; Sun, Xiankai. / A cell permeable peptide analog as a potential-specific PET imaging probe for prostate cancer detection. In: Amino Acids. 2011 ; Vol. 41, No. 5. pp. 1093-1101.
@article{06fbedcf7c53468688af21cbcfb12cb0,
title = "A cell permeable peptide analog as a potential-specific PET imaging probe for prostate cancer detection",
abstract = "Non-invasive detection of prostate cancer or metastases still remains a challenge in the field of molecular imaging. In our recent work of screening arginine- or lysine-rich peptides for intracellular delivery of a therapeutic agent into prostate cancer cells, an arginine-rich cell permeable peptide (NH2GR11) was found with an unexpectedly preferential uptake in prostate cancer cell lines. The goal of this work was to develop this peptide as a positron emission tomography (PET) imaging probe for specific detection of distant prostate cancer metastases. The optimal length of arginine-rich peptides was evaluated by the cell uptake efficiency of three fluorescein isothiocyanate (FITC)-tagged oligoarginines (NHGR9, NHGR11, and NHGR13) in four human prostate cell lines (LNCaP, PZHPV- 7, DU145, and PC3). Of the three oligoarginines, NH 2GR11 showed the highest cell uptake and internalization efficiency with its subcellular localization in cytosol. The biodistribution of FITC-NHGR9, FITC-NHGR11, and FITC-NHGR13 performed in control nude mice displayed the unique preferential accumulation of FITC-NHGR11 in the prostate tissue. Further in vivo evaluation of FITCNHGR11 in PC3 tumor-bearing nude mice revealed elevated uptake of this peptide in tumors as compared to other organs. In vivo pharmacokinetics evaluated with 64Cu-labeled NH2GR11 showed that the peptide was rapidly cleared from the blood (t1/2 = 10.7 min) and its elimination half-life was 17.2 h. The PET imaging specificity of 64Cu-labled NH2GR11 was demonstrated for the detection of prostate cancer in a comparative imaging experiment using two different human cancer xenograft models.",
keywords = "Cu, Cell permeable peptide, PET, Prostate cancer",
author = "Guiyang Hao and Jian Zhou and Yi Guo and Long, {Michael A.} and Tiffani Anthony and Jennifer Stanfield and Hsieh, {Jer Tsong} and Xiankai Sun",
year = "2011",
month = "11",
doi = "10.1007/s00726-010-0515-5",
language = "English (US)",
volume = "41",
pages = "1093--1101",
journal = "Amino Acids",
issn = "0939-4451",
publisher = "Springer Wien",
number = "5",

}

TY - JOUR

T1 - A cell permeable peptide analog as a potential-specific PET imaging probe for prostate cancer detection

AU - Hao, Guiyang

AU - Zhou, Jian

AU - Guo, Yi

AU - Long, Michael A.

AU - Anthony, Tiffani

AU - Stanfield, Jennifer

AU - Hsieh, Jer Tsong

AU - Sun, Xiankai

PY - 2011/11

Y1 - 2011/11

N2 - Non-invasive detection of prostate cancer or metastases still remains a challenge in the field of molecular imaging. In our recent work of screening arginine- or lysine-rich peptides for intracellular delivery of a therapeutic agent into prostate cancer cells, an arginine-rich cell permeable peptide (NH2GR11) was found with an unexpectedly preferential uptake in prostate cancer cell lines. The goal of this work was to develop this peptide as a positron emission tomography (PET) imaging probe for specific detection of distant prostate cancer metastases. The optimal length of arginine-rich peptides was evaluated by the cell uptake efficiency of three fluorescein isothiocyanate (FITC)-tagged oligoarginines (NHGR9, NHGR11, and NHGR13) in four human prostate cell lines (LNCaP, PZHPV- 7, DU145, and PC3). Of the three oligoarginines, NH 2GR11 showed the highest cell uptake and internalization efficiency with its subcellular localization in cytosol. The biodistribution of FITC-NHGR9, FITC-NHGR11, and FITC-NHGR13 performed in control nude mice displayed the unique preferential accumulation of FITC-NHGR11 in the prostate tissue. Further in vivo evaluation of FITCNHGR11 in PC3 tumor-bearing nude mice revealed elevated uptake of this peptide in tumors as compared to other organs. In vivo pharmacokinetics evaluated with 64Cu-labeled NH2GR11 showed that the peptide was rapidly cleared from the blood (t1/2 = 10.7 min) and its elimination half-life was 17.2 h. The PET imaging specificity of 64Cu-labled NH2GR11 was demonstrated for the detection of prostate cancer in a comparative imaging experiment using two different human cancer xenograft models.

AB - Non-invasive detection of prostate cancer or metastases still remains a challenge in the field of molecular imaging. In our recent work of screening arginine- or lysine-rich peptides for intracellular delivery of a therapeutic agent into prostate cancer cells, an arginine-rich cell permeable peptide (NH2GR11) was found with an unexpectedly preferential uptake in prostate cancer cell lines. The goal of this work was to develop this peptide as a positron emission tomography (PET) imaging probe for specific detection of distant prostate cancer metastases. The optimal length of arginine-rich peptides was evaluated by the cell uptake efficiency of three fluorescein isothiocyanate (FITC)-tagged oligoarginines (NHGR9, NHGR11, and NHGR13) in four human prostate cell lines (LNCaP, PZHPV- 7, DU145, and PC3). Of the three oligoarginines, NH 2GR11 showed the highest cell uptake and internalization efficiency with its subcellular localization in cytosol. The biodistribution of FITC-NHGR9, FITC-NHGR11, and FITC-NHGR13 performed in control nude mice displayed the unique preferential accumulation of FITC-NHGR11 in the prostate tissue. Further in vivo evaluation of FITCNHGR11 in PC3 tumor-bearing nude mice revealed elevated uptake of this peptide in tumors as compared to other organs. In vivo pharmacokinetics evaluated with 64Cu-labeled NH2GR11 showed that the peptide was rapidly cleared from the blood (t1/2 = 10.7 min) and its elimination half-life was 17.2 h. The PET imaging specificity of 64Cu-labled NH2GR11 was demonstrated for the detection of prostate cancer in a comparative imaging experiment using two different human cancer xenograft models.

KW - Cu

KW - Cell permeable peptide

KW - PET

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84855222648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855222648&partnerID=8YFLogxK

U2 - 10.1007/s00726-010-0515-5

DO - 10.1007/s00726-010-0515-5

M3 - Article

C2 - 20221650

AN - SCOPUS:84855222648

VL - 41

SP - 1093

EP - 1101

JO - Amino Acids

JF - Amino Acids

SN - 0939-4451

IS - 5

ER -